Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 03 May 2017
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Apr 2017 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.
- 28 Apr 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.